KR20070011483A - Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산 - Google Patents

Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산 Download PDF

Info

Publication number
KR20070011483A
KR20070011483A KR1020067023661A KR20067023661A KR20070011483A KR 20070011483 A KR20070011483 A KR 20070011483A KR 1020067023661 A KR1020067023661 A KR 1020067023661A KR 20067023661 A KR20067023661 A KR 20067023661A KR 20070011483 A KR20070011483 A KR 20070011483A
Authority
KR
South Korea
Prior art keywords
compound
patient
formula
ikk
effective amount
Prior art date
Application number
KR1020067023661A
Other languages
English (en)
Korean (ko)
Inventor
엘-브다오위 하다
올라프 리첼러
데이비드 제이 알도우스
폴 죠셉 콕스
Original Assignee
아벤티스 파마슈티칼스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아벤티스 파마슈티칼스 인크. filed Critical 아벤티스 파마슈티칼스 인크.
Publication of KR20070011483A publication Critical patent/KR20070011483A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067023661A 2004-05-12 2005-05-11 Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산 KR20070011483A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57014604P 2004-05-12 2004-05-12
US60/570,146 2004-05-12

Publications (1)

Publication Number Publication Date
KR20070011483A true KR20070011483A (ko) 2007-01-24

Family

ID=34969825

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067023661A KR20070011483A (ko) 2004-05-12 2005-05-11 Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산

Country Status (23)

Country Link
EP (1) EP1747215A1 (es)
JP (1) JP2007537266A (es)
KR (1) KR20070011483A (es)
CN (1) CN1950359A (es)
AR (1) AR049274A1 (es)
AU (1) AU2005245834A1 (es)
BR (1) BRPI0511029A (es)
CA (1) CA2566213A1 (es)
EC (1) ECSP066992A (es)
GT (1) GT200500111A (es)
IL (1) IL178992A0 (es)
MA (1) MA28553B1 (es)
MX (1) MXPA06012870A (es)
NO (1) NO20065719L (es)
PA (1) PA8633101A1 (es)
PE (1) PE20060269A1 (es)
RU (1) RU2006143758A (es)
SV (1) SV2006002111A (es)
TN (1) TNSN06338A1 (es)
TW (1) TW200605881A (es)
UY (1) UY28897A1 (es)
WO (1) WO2005113544A1 (es)
ZA (1) ZA200608712B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE102004033406A1 (de) 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2563774B1 (en) * 2010-04-27 2014-03-12 Hutchison Medipharma Limited Pyrimidinyl indole compounds
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
CN106588803A (zh) * 2016-11-16 2017-04-26 西南科技大学 一种制备5‑乙酰基异噁唑的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237722A1 (de) * 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase

Also Published As

Publication number Publication date
ECSP066992A (es) 2006-12-29
TNSN06338A1 (en) 2008-02-22
PE20060269A1 (es) 2006-05-11
EP1747215A1 (en) 2007-01-31
AR049274A1 (es) 2006-07-12
RU2006143758A (ru) 2008-06-27
CA2566213A1 (en) 2005-12-11
GT200500111A (es) 2006-05-09
WO2005113544A1 (en) 2005-12-01
NO20065719L (no) 2006-12-12
MXPA06012870A (es) 2007-02-15
IL178992A0 (en) 2007-03-08
BRPI0511029A (pt) 2007-11-27
SV2006002111A (es) 2006-01-30
ZA200608712B (en) 2008-06-25
TW200605881A (en) 2006-02-16
JP2007537266A (ja) 2007-12-20
MA28553B1 (fr) 2007-04-03
UY28897A1 (es) 2005-12-30
AU2005245834A1 (en) 2005-12-01
CN1950359A (zh) 2007-04-18
PA8633101A1 (es) 2006-01-23

Similar Documents

Publication Publication Date Title
KR20070011483A (ko) Ｉｋｂ 키나제 억제제로서의 실질적으로 순수한2-｛[2-(2-메틸아미노-피리미딘-4-일)-1ｈ-인돌-5-카르보닐]-아미노｝-3-(페닐피리딘-2-일-아미노)-프로피온산
KR102293952B1 (ko) 피리다지논 아미드 유도체
KR102340654B1 (ko) 키나제 저해제
US20040229889A1 (en) HDAC inhibitor
EP3134410B1 (en) Inhibiting the transient receptor potential a1 ion channel
EP3048099A2 (en) Inhibitors of kinase activity
JP2021138728A (ja) ［４−（１，３，３−トリメチル−２−オキソ−３，４−ジヒドロ−１ｈ−キノキサリン−７−イル）フェノキシ］エチルオキシ化合物またはその塩
JP2015524837A (ja) キナーゼ阻害剤
ES2525756T3 (es) Imidazo [1,2-a] piridinas como moduladores de JNK
CA2808959A1 (en) Quinoline and quinoxaline derivatives as kinase inhibitors
KR102410255B1 (ko) 아미드 화합물, 그의 제조방법, 및 rna 함유 및/또는 dna 함유 바이러스에 의해 유발된 질환, 및 동반 질환의 예방 및 치료제로서의 용도
JP2014528403A (ja) ｐ３ｉＭＡＰキナーゼ阻害剤としてのｌ−ピラゾリル−３−（４−（（２−アニリノピリミジン−４−イル）オキシ）ナフタレン−１−イル）尿素
CA2826387A1 (en) Method of inhibiting hamartoma tumor cells
RU2661895C2 (ru) Соединение сложного эфира гуанидинобензойной кислоты
KR20140094547A (ko) 1-(5,6-다이클로로-1h-벤조[d]이미다졸-2-일)-1h-피라졸-4-카르복실산의 메글루민 염 제형
CN110997681B (zh) 作为腺苷受体拮抗剂的噻唑并吡啶衍生物
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
US20070142417A1 (en) Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
JP6441830B2 (ja) カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
ES2427968T3 (es) Nuevos derivados de indol que tienen un grupo carbamoilo, un grupo ureido y un grupo oxi sustituido
CN114621206B (zh) 一种5-取代的嘧啶二胺类衍生物及其制备方法与应用
ES2785313T3 (es) Acilguanidinas para el tratamiento de la artrosis
WO2015110092A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
CN117337290A (zh) 三并环类泛素特异性蛋白酶1抑制剂及其用途

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid